Drug Pipeline

Linvoseltamab Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
19
Active Studies
14
Recruiting
6
Phase 3
6
Top Sponsors
2
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-11 NCT07393282
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering…
Recruitment opened
2026-06-05 NCT06140524
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma…
Trial sites expanded: 20 -> 39 locations
New Trial Filings, Last 30 Days
First PostedTrialPhaseStatus
2026-06-03 NCT07624513 Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction… Phase 3 Not Yet Recruiting
2026-05-27 NCT07609940 Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of… Phase 4 Not Yet Recruiting
Active Studies by Phase
Phase 4
1
Phase 3
5
Phase 2/3
1
Phase 2
4
Phase 1/2
6
Phase 1
2
Active Trials
NCT IDTitleConditionStatus
Phase 4
NCT07609940 Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of… Relapsed/Refractory Multiple Myeloma (RRMM) Not Yet Recruiting
Phase 3
NCT05730036 A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab… Relapsed Refractory Multiple Myeloma (RRMM) Recruiting
NCT06932562 A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment… Multiple Myeloma Recruiting
NCT07222761 A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination… Relapsed and/or Refractory Multiple Myeloma (RRMM) Recruiting
NCT07393282 A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering… High Risk Smoldering Multiple Myeloma (HR-SMM) Recruiting
NCT07624513 Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction… Multiple Myeloma Not Yet Recruiting
Phase 2/3
NCT07428369 A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly… Multiple Myeloma (MM) Not Yet Recruiting
Phase 2
NCT06910124 Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to… Multiple Myeloma Recruiting
NCT06140524 A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma… Monoclonal Gammopathy of Undetermined Significance (MGUS) Recruiting
NCT05955508 A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult… Smoldering Multiple Myeloma (SMM) Active, Not Recruiting
NCT07009899 BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM) Multiple Myeloma Not Yet Recruiting
Phase 1/2
NCT07181941 Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory… Recurrent Multiple Myeloma Recruiting
NCT06669247 A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With… Relapsed/Refractory Multiple Myeloma Recruiting
NCT07455851 A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult… Relapsed Refractory Multiple Myeloma (RRMM) Recruiting
NCT03761108 Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple… Multiple Myeloma Recruiting
NCT06292780 A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory… Relapsed/Refractory Systemic Light Chain Amyloidosis Recruiting
NCT05828511 A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and… Multiple Myeloma Recruiting
Phase 1
NCT05137054 A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other… Multiple Myeloma Recruiting
NCT06369467 Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With… Food Allergy Recruiting
Sponsors Running Linvoseltamab Trials
Disease Areas
Get alerts when Linvoseltamab trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free